ADAM19: biological characteristics and implications in disease pathology and clinical applications

This article critically examines ADAM19-mediated inflammatory remodeling within five distinct subtypes of solid tumors prone to inflammation, employing non-neoplastic inflammatory states strictly as a comparative reference. As a transmembrane protease belonging to the ADAM family, ADAM19 undergoes maturation through plasmin-dependent cleavage, with its expression tightly regulated by both transcriptional and epigenetic controls. Although dysregulated ADAM19 levels are evident in various inflammatory lesions and malignancies, its context-specific dual biological roles necessitate a systematic synthesis.

ADAM19 modulates signal transduction pathways by processing pro-inflammatory cytokines. While it generally expedites progression in the majority of solid tumors, it paradoxically suppresses tumor growth in prostate cancer and specific osteosarcoma subsets; this functional dichotomy is orchestrated by intricate non-coding RNA networks and interconnected signaling cascades. Preclinical evidence indicates that ADAM19 holds promise as both a biomarker and a therapeutic target, yet robust clinical validation remains lacking. Consequently, this review delineates ADAM19 structural characteristics, contrasts its tissue-specific regulatory mechanisms across different malignancies, and integrates exosomal and immune-related signaling axes to reconcile contradictory research findings. We highlight pivotal translational challenges, notably tissue-dependent functional heterogeneity and the scarcity of selective ADAM19 inhibitors, while proposing targeted research directions to advance future precision oncology strategies centered on ADAM19.